First Manhattan CO. LLC. Decreases Stock Position in Amgen Inc. $AMGN

First Manhattan CO. LLC. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 3.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,933 shares of the medical research company’s stock after selling 3,113 shares during the quarter. First Manhattan CO. LLC.’s holdings in Amgen were worth $30,418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Dogwood Wealth Management LLC increased its position in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC increased its position in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen in the fourth quarter worth $26,000. Manning & Napier Advisors LLC boosted its holdings in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new position in shares of Amgen in the fourth quarter worth $33,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AMGN. Canaccord Genuity Group began coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 price target for the company. Morgan Stanley raised their price target on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 9th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Sunday. Argus cut their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Finally, Barclays began coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $354.42.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $341.66 on Thursday. The firm has a market capitalization of $184.40 billion, a price-to-earnings ratio of 23.78, a P/E/G ratio of 3.49 and a beta of 0.42. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The stock has a fifty day moving average of $341.01 and a 200 day moving average of $345.86. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.